Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05889767
Other study ID # IRB-22-28-STW
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 10, 2023
Est. completion date August 1, 2023

Study information

Verified date June 2023
Source Oklahoma State University
Contact Bryant H Keirns, MS
Phone 3166891711
Email bryant.keirns@okstate.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Exercise acutely increases gut permeability and inflammation, even in healthy populations. However, whether this response differs in groups at-risk for CVD that present with low-grade inflammation (e.g., normal-weight obesity) has yet to be examined. The investigators aim to measure serum indicators of gut permeability in those with normal-weight obesity pre- and post-short, intense exercise and sustained, moderate exercise


Description:

The investigator's overall goal is to examine how indicators of gut permeability change in response to exercise in individuals with normal-weight obesity (i.e., normal body mass index [BMI] and high body fat percent) relative to those with a normal BMI and low body fat percent and those with a BMI in the obesity range and high body fat percent. The investigators will examine indicators of gut permeability (specified in primary outcomes) in response to a short, intense bout of exercise (i.e., VO2 max test on a cycle ergometer) and sustained, moderate bout of exercise (i.e., 45 minutes at 65% measured VO2 max on a cycle ergometer). Additionally, the investigators will measure basic anthropometrics, blood lipids and glucose, and body composition with DXA.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date August 1, 2023
Est. primary completion date August 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: Control group: normal BMI, body fat percentage < 25% (male) or < 35% (female) Normal-weight obesity: normal BMI, body fat percentage > 25% (male) or > 35% (female) Overt obesity: BMI in obesity range, body fat percentage > 25% (male) or > 35% (female) Exclusion Criteria: - Presence of pacemaker - Pregnant - Postmenopausal status - History of chronically using of tobacco products, illicit drugs, anti-inflammatory drugs (e.g., NSAIDs), lipid lowering drugs - Recent use of antibiotics (< 6 weeks) and NSAIDs (< 3 days) - Established cardiometabolic disease (e.g., cardiovascular disease, type 2 diabetes) diseases inflammatory in nature (e.g., rheumatoid arthritis, inflammatory bowel disease), and/or diagnosed irritable bowel syndrome.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Exercise tests (VO2 max test and 45-minute exercise session at 65% VO2 max)
All participants will complete two exercise sessions: VO2 max test on a cycle ergometer Moderate exercise session (45 minutes at 65% measured VO2 max)

Locations

Country Name City State
United States 208 Nancy Randolph Davis, Oklahoma State University Stillwater Oklahoma

Sponsors (1)

Lead Sponsor Collaborator
Oklahoma State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Body fat percent assessment with dual-energy X-ray absorptiometry (DXA). The investigators will perform DXA scans on all participants to assess body fat percent. Approximately 8 months
Other Absolute body fat assessment with dual-energy X-ray absorptiometry (DXA) The investigators will perform DXA scans on all participants to assess absolute body fat in kilograms. Approximately 8 months
Other Lean mass percent assessment with dual-energy X-ray absorptiometry (DXA) The investigators will perform DXA scans on all participants to assess lean mass percent. Approximately 8 months
Other Absolute lean mass assessment with dual-energy X-ray absorptiometry (DXA) The investigators will perform DXA scans on all participants to assess absolute lean mass in kilograms. Approximately 8 months
Other Absolute visceral fat mass assessment with dual-energy X-ray absorptiometry (DXA) The investigators will perform DXA scans on all participants to assess absolute visceral mass in grams. Approximately 8 months
Other Lipid panel with Abbott Piccolo Xpress Clinical Chemistry Analyzer The investigators will perform a lipid panel on all participants. Approximately 8 months
Primary Serum concentrations of FABP2 following short, intense exercise The investigators will examine peak and absolute change in this indicator of gut permeability after the VO2 max test on a cycle ergometer. Approximately 8 months
Primary Serum concentrations of LBP following short, intense exercise The investigators will examine peak and absolute change in this indicator of gut permeability after the VO2 max test on a cycle ergometer. Approximately 8 months
Primary Serum concentrations of sCD14 following short, intense exercise The investigators will examine peak and absolute change in this indicator of gut permeability after the VO2 max test on a cycle ergometer. Approximately 8 months
Primary Serum concentrations of FABP2 following sustained, moderate exercise The investigators will examine peak and absolute change in this indicator of gut permeability after 45-minutes of exercise at 65% VO2 max on a cycle ergometer. Approximately 8 months
Primary Serum concentrations of IL-6 following sustained, moderate exercise The investigators will examine peak and absolute change in this inflammatory marker after 45-minutes of exercise at 65% VO2 max on a cycle ergometer. Approximately 8 months
Secondary VO2 Max The investigators will compare VO2 max after the short, intense exercise session across study groups. Approximately 8 months
Secondary Respiratory exchange ratio (RER) during VO2 max test The investigators will compare RER dynamics during the short, intense exercise session across study groups. Approximately 8 months
Secondary Maximum workload during exercise sessions The investigators will compare workload dynamics in watts during the short, intense and moderate, sustained exercise session across study groups. Approximately 8 months
Secondary Heart rate dynamics during exercise sessions The investigators will compare heart rate dynamics during the short, intense and moderate, sustained exercise session across study groups. Approximately 8 months
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2